Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
170900.KS
Top 10 Correlated ETFs
170900.KS
Top 10 Correlated Stocks
170900.KS
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 65.77K | 67.24K | 72.56K | 69.53K | 5.66K | |
| Net income per share | -639.39 | 949.09 | 8.4K | 3.21K | 122.18 | |
| Operating cash flow per share | 6.07K | 5.94K | 6.67K | 3.2K | 470.68 | |
| Free cash flow per share | 4.7K | 4.91K | 4.45K | -1.79K | -296.15 | |
| Cash per share | 22.93K | 25.94K | 28.02K | 30.43K | 2.9K | |
| Book value per share | 68.87K | 68.66K | 76.54K | 76.09K | 6.26K | |
| Tangible book value per share | 67.33K | 67.33K | 74.67K | 73.64K | 5.89K | |
| Share holders equity per share | 68.87K | 68.66K | 76.54K | 76.09K | 6.26K | |
| Interest debt per share | 22.39K | 25.72K | 25.41K | 25.13K | 2.92K | |
| Market cap | 1033.72B | 843.84B | 805.02B | 696.17B | 6849.9B | |
| Enterprise value | 1022.88B | 835.87B | 787.14B | 754.66B | 6955.88B | |
| P/E ratio | -191.59 | 105.36 | 11.35 | 25.69 | 534.47 | |
| Price to sales ratio | 1.86 | 1.49 | 1.31 | 1.19 | 11.55 | |
| POCF ratio | 20.18 | 16.83 | 14.31 | 25.75 | 138.74 | |
| PFCF ratio | 26.08 | 20.37 | 21.46 | -46.02 | -220.49 | |
| P/B Ratio | 1.78 | 1.46 | 1.25 | 1.08 | 10.44 | |
| PTB ratio | 1.78 | 1.46 | 1.25 | 1.08 | 10.44 | |
| EV to sales | 1.84 | 1.47 | 1.29 | 1.29 | 11.73 | |
| Enterprise value over EBITDA | 46.61 | 19.46 | 6.72 | 12.91 | 184.68 | |
| EV to operating cash flow | 19.97 | 16.67 | 13.99 | 27.92 | 140.88 | |
| EV to free cash flow | 25.8 | 20.17 | 20.99 | -49.89 | -223.91 | |
| Earnings yield | -0.01 | 0.01 | 0.09 | 0.04 | 0 | |
| Free cash flow yield | 0.04 | 0.05 | 0.05 | -0.02 | 0 | |
| Debt to equity | 0.1 | 0.12 | 0.18 | 0.24 | 0.24 | |
| Debt to assets | 0.35 | 0.39 | 0.36 | 0.35 | 0.41 | |
| Net debt to EBITDA | -0.49 | -0.19 | -0.15 | 1 | 2.81 | |
| Current ratio | 1.88 | 1.59 | 2.1 | 3.13 | 1.93 | |
| Interest coverage | 2.79 | 5.76 | 7.48 | 6.55 | 2.78 | |
| Income quality | -9.5 | 6.26 | 0.79 | 1 | 3.85 | |
| Dividend Yield | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Payout ratio | -0.78 | 0.53 | 0.12 | 0.31 | 0.66 | |
| Sales general and administrative to revenue | 0.1 | 0.08 | 0.07 | 0.06 | 0.07 | |
| Research and developement to revenue | 0.14 | 0.13 | 0.12 | 0.13 | 0.14 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | |
| Capex to operating cash flow | -0.23 | -0.17 | -0.33 | -1.56 | -1.63 | |
| Capex to revenue | -0.02 | -0.02 | -0.03 | -0.07 | -0.14 | |
| Capex to depreciation | -0.53 | -0.43 | -0.91 | -2.11 | -4.03 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 31.48K | 38.29K | 120.3K | 74.15K | 4.15K | |
| ROIC | 0.04 | 0.06 | 0.07 | 0.04 | 0.02 | |
| Return on tangible assets | -0.01 | 0.01 | 0.07 | 0.03 | 0.01 | |
| Graham Net | -8.98K | -11.72K | -8.2K | -3.5K | -980.16 | |
| Working capital | 193.25B | 157.5B | 237.2B | 314.53B | 255.46B | |
| Tangible asset value | 568.19B | 568.16B | 630.09B | 621.37B | 617.97B | |
| Net current asset value | 94.27B | 57.18B | 90.4B | 123.67B | 71.39B | |
| Invested capital | 0.31 | 0.36 | 0.32 | 0.32 | 0.46 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 31.05B | 30.23B | 34.76B | 31.54B | 33.77B | |
| Average inventory | 101.56B | 103.83B | 109.57B | 104.56B | 104.58B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 40.56 | 38.5 | 46.15 | 38.07 | 43.89 | |
| Days of inventory on hand | 130.77 | 137.27 | 139.25 | 126.21 | 127.53 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 9 | 9.48 | 7.91 | 9.59 | 8.32 | |
| Inventory turnover | 2.79 | 2.66 | 2.62 | 2.89 | 2.86 | |
| ROE | -0.01 | 0.01 | 0.11 | 0.04 | 0.02 | |
| Capex per share | -1.37K | -1.03K | -2.22K | -5K | -766.83 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 16.7K | 17.48K | 18K | 1.45K | 1.55K | |
| Net income per share | 90.31 | 742.53 | 1.37K | -54.7 | 28.69 | |
| Operating cash flow per share | 742.57 | 2.51K | 2.4K | 15.98 | 55.76 | |
| Free cash flow per share | -719.74 | 329.37 | 14.48 | -265.11 | -159.02 | |
| Cash per share | 30.01K | 28.66K | 40.21K | 2.89K | 0 | |
| Book value per share | 74.99K | 75.41K | 77.44K | 6.24K | 6.2K | |
| Tangible book value per share | 72.51K | 71.93K | 73.25K | 5.87K | 6.2K | |
| Share holders equity per share | 74.99K | 75.41K | 77.44K | 6.24K | 6.2K | |
| Interest debt per share | 24.51K | 24.45K | 35.55K | 2.86K | 13.02 | |
| Market cap | 706.29B | 725.7B | 634.56B | 7533.47B | 6134.09B | |
| Enterprise value | 702.71B | 751.69B | 726.42B | 7639.44B | 6134.09B | |
| P/E ratio | 231.7 | 28.96 | 13.74 | -327.24 | 508.02 | |
| Price to sales ratio | 5.01 | 4.92 | 4.18 | 49.26 | 37.56 | |
| POCF ratio | 112.72 | 34.28 | 31.33 | 4.48K | 1.05K | |
| PFCF ratio | -116.29 | 261.11 | 5.19K | -270.07 | -366.62 | |
| P/B Ratio | 1.12 | 1.14 | 0.97 | 11.48 | 9.41 | |
| PTB ratio | 1.12 | 1.14 | 0.97 | 11.48 | 9.41 | |
| EV to sales | 4.99 | 5.1 | 4.78 | 49.96 | 37.56 | |
| Enterprise value over EBITDA | 94.18 | 69.06 | 42.96 | -2.38K | 1.08K | |
| EV to operating cash flow | 112.15 | 35.51 | 35.86 | 4.54K | 1.05K | |
| EV to free cash flow | -115.7 | 270.46 | 5.94K | -273.87 | -366.62 | |
| Earnings yield | 0 | 0.01 | 0.02 | 0 | 0 | |
| Free cash flow yield | -0.01 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.24 | 0.16 | 0.27 | 0.24 | 0 | |
| Debt to assets | 0.36 | 0.36 | 0.42 | 0.41 | 0.44 | |
| Net debt to EBITDA | -0.48 | 2.39 | 5.43 | -32.96 | 0 | |
| Current ratio | 2.93 | 2.2 | 2.2 | 1.93 | 2.24 | |
| Interest coverage | 0 | 0 | 0 | 0 | 3.21 | |
| Income quality | 8.22 | 3.38 | 1.75 | -0.29 | 1.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.07 | 0.07 | 0.07 | 0.07 | 0.47 | |
| Research and developement to revenue | 0.16 | 0.12 | 0.13 | 0.15 | 0 | |
| Intangibles to total assets | 0.02 | 0.03 | 0.03 | 0.03 | 0 | |
| Capex to operating cash flow | -1.97 | -0.87 | -0.99 | -17.59 | -3.85 | |
| Capex to revenue | -0.09 | -0.12 | -0.13 | -0.19 | -0.14 | |
| Capex to depreciation | -2.47 | -3.7 | -4.07 | -5.87 | -4.32 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 12.34K | 35.49K | 48.82K | 2.77K | 2K | |
| ROIC | 0 | 0.01 | 0.01 | -0.01 | 0 | |
| Return on tangible assets | 0 | 0.01 | 0.01 | -0.01 | 0 | |
| Graham Net | -5.62K | -7.24K | -10.51K | -977.21 | -4.96K | |
| Working capital | 307.51B | 251.11B | 315.78B | 255.46B | 308.91B | |
| Tangible asset value | 611.88B | 606.99B | 618.12B | 617.97B | 0 | |
| Net current asset value | 111B | 104.87B | 95.26B | 71.39B | 37.48B | |
| Invested capital | 0.33 | 0.32 | 0.46 | 0.46 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 41.67 | 34.64 | 40.56 | 40.43 | 0 | |
| Days of inventory on hand | 139.32 | 126.14 | 133.08 | 117.47 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.16 | 2.6 | 2.22 | 2.23 | 0 | |
| Inventory turnover | 0.65 | 0.71 | 0.68 | 0.77 | 0 | |
| ROE | 0 | 0.01 | 0.02 | -0.01 | 0 | |
| Capex per share | -1.46K | -2.18K | -2.39K | -281.1 | -214.78 |
Frequently Asked Questions
What is Dong-A ST Co., Ltd. stock symbol ?
Dong-A ST Co., Ltd. is a US stock and trading under the symbol 170900.KS
What is Dong-A ST Co., Ltd. stock quote today ?
Dong-A ST Co., Ltd. stock price is $49800 today.
Is Dong-A ST Co., Ltd. stock public?
Yes, Dong-A ST Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 5.93K
- Market Capitalization 430.49B
- Employee 1.65K
- Headquarters Seoul,US
- IPO Date 2013-04-05
-
Website
https://www.donga-st.com 
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide. It offers various ethical drugs, including Closerin for active pulmonary and extra-pulmonary tuberculosis; Dulastin and Leucostim for neutropenia in patients receiving myelosuppressive chemotherapy; Eporon for anemia associated with chronic renal failure; Gemcit for non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin for infertility and annovulation; Growtropin II for growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel for breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone for use in functional dyspepsia treatment; Stillen for the treatment of gastritis; Suganon for diabetes treatment; Terizidone for active pulmonary and extra-pulmonary tuberculosis; and Zydena for erectile dysfunction treatment. The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high technology medical devices, custom made products, and sets of artificial cardiac circuits for use in open-heart surgery. Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.
